Meta AnalysisID 6380
阿司匹林联合麝香保心丸治疗冠心病的临床疗效与安全性：系统评价与Meta分析
CRD42022340902
P（Population) ：Patients with coronary heart disease I（Intervention) : Asipirin in combination with shexiangbaoxin pill C（Comparison): Asipirin alone O（Outcome）: Improvement of symptoms S（Study design）：Cross sectional stu
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6380
- Evidence Id
- 14938
- Core Evidence Id
- 14938
- Source Meta Analysis Id
- 6363
- Herb2 Meta Analysis Id
- HBMA006363
- Crd Id
- CRD42022340902
- Title
- Clinical efficacy and safety of Aspirin combined with Shexiang Baoxin Pill in the treatment of coronary heart disease: A systematic review and meta-analysis
- Review Question
- P（Population) ：Patients with coronary heart disease I（Intervention) : Asipirin in combination with shexiangbaoxin pill C（Comparison): Asipirin alone O（Outcome）: Improvement of symptoms S（Study design）：Cross sectional study
- Study Type Included
- Included in randomized controlled trials
- Condition Being Studied
- Coronary atherosclerotic heart disease, referred to as coronary heart disease, is a series of symptoms of myocardial ischemia caused by partial or complete blockage of coronary artery.
- Participant
- To be included, trials were required to meet the following criteria: (1) patients were included in the studies according to diagnostic criteria of coronary heart disease established by the WHO, International Society of Cardiology and Association (ISCA), Internal Medicine, 7th edition ( IM-7th), Practice of Internal Medicine, 14th edition ( PIM-14th), Guidelines for the Diagnosis of Cardiovascular Diseases in Internal Medicine, 3rd edition (GIM-3rd) or conventional diagnostic criteria (CDC) including assessment of angina pectoris and electrocardiogram (ECG) results; (2) the study was conducted as a randomized controlled trial;
- Animal
- Human Disease Modelled
- Intervention
- aspirin in combination with shexiangbaoxin pill
- Comparator Control
- aspirin monotherapy
- Main Outcome
- Efficacy of the randomized controlled trials (RCTs) for coronary heart disease was determined on the basis of angina pectoris and ECG results
- Outcome Measure
- Additional Outcome
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Aspirin; Coronary Disease; Drugs, Chinese Herbal; Humans; Treatment Outcome; shexiang baoxin
- Contact
- Ling Liu [email protected]
- Organisational Affiliation
- The second xiangya hospital of central south university
- Funding Source
- Ling Liu
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-06-20
- Registration Date
- 2022-06-30
- Anticipated Start Date
- 2022-06-18
- Anticipated Completion Date
- 2022-09-20
- Title Cn
- 阿司匹林联合麝香保心丸治疗冠心病的临床疗效与安全性：系统评价与Meta分析
- Title En
- Clinical efficacy and safety of Aspirin combined with Shexiang Baoxin Pill in the treatment of coronary heart disease: A systematic review and meta-analysis
- Bilingual Status
- complete